Nasdaq · CIK 0001971532
TELO Telomir Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing May 22, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
2
with a Form 4 at this company
Signals
Open-market buys and sells at Telomir Pharmaceuticals, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 8 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | Erez Aminov CEO and Chairman | AGrant or award Incentive Stock Options (right to buy)derivative | +1,960,170 | - | - | 1,960,170 | May 22, 2026 |
| May 21, 2026 | Erez Aminov CEO and Chairman | DDisposition to issuer Incentive Stock Options (right to buy)derivative | -1,960,170 | - | - | 0 | May 22, 2026 |
| May 21, 2026 | Erez Aminov CEO and Chairman | AGrant or award Non-Qualified Stock Options (right to buy)derivative | +2,000,000 | - | - | 2,000,000 | May 22, 2026 |
| May 21, 2026 | Erez Aminov CEO and Chairman | DDisposition to issuer Non-Qualified Stock Options (right to buy)derivative | -2,000,000 | - | - | 0 | May 22, 2026 |
| Apr 22, 2026 | Erez Aminov CEO and Chairman | JOther Common Stock | +7,319,710 | $1.37 | $10M | 7,319,710 | Apr 24, 2026 |
| May 28, 2025 | Erez Aminov CEO and Chairman | AGrant or award Non-Qualified Optionsderivative | +2,000,000 | $0.00 | $0 | 2,000,000 | May 30, 2025 |
| May 28, 2025 | Erez Aminov CEO and Chairman | AGrant or award Restricted Stock Units (RSUs)derivative | +400,000 | $0.00 | $0 | 400,000 | May 30, 2025 |
| Nov 21, 2024 | Bay Shore Trust owner | GGift Common Stock (right to buy)derivativeindirect: By Trust | -100,000 | - | - | 2,339,025 | Nov 25, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.